Oxygenta Pharma

{
  "main_header": {
    "sid": 798135,
    "name": "Oxygenta Pharma",
    "stock_name": "Oxygenta Pharma",
    "full_name": "Oxygenta Pharmaceutical Ltd",
    "name_url": "stocks-analysis/oxygenta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "59.90",
    "chg": 0.97,
    "chgp": "1.65%",
    "dir": 1,
    "prev_price": "58.93",
    "mcapval": "218.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524636,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE102E01018",
    "curr_date": "Feb 11",
    "curr_time": "",
    "bse_nse_vol": "9.65 k",
    "exc_status": "Active",
    "traded_date": "Feb 11, 2026",
    "traded_date_str": "2026 02 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/oxygenta-pharma-798135-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3824182",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/OxygentaPharmac_mojoScore_3824182.png",
        "date": "2026-02-06 10:10:03",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with the most recent insights into the company’s performance and outlook."
      },
      {
        "title": "Are Oxygenta Pharmaceutical Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-oxygenta-pharmaceutical-ltd-latest-results-good-or-bad-3822934",
        "imagepath": "",
        "date": "2026-02-05 19:29:52",
        "description": "Oxygenta Pharmaceutical Ltd's latest financial results for the quarter ending December 2025 present a complex picture of growth and ongoing operational challenges. The company reported a significant revenue surge of 137.27% quarter-on-quarter, reaching ₹33.93 crores, which reflects a seasonal demand typical in the pharmaceutical sector. However, this top-line growth did not translate into profitability, as the company experienced a net loss of ₹4.84 crores, representing a 23.16% decline year-on-year.\n\nThe operational metrics indicate persistent difficulties. The operating loss widened to ₹4.08 crores, with an operating margin of negative 12.02%. While this margin shows some improvement from the previous quarter, it remains a concern, especially given the negative operating margins reported in the same quarter last year. The company's negative book value of ₹-6.77 per share raises fundamental questions about..."
      },
      {
        "title": "Oxygenta Pharmaceutical Q3 FY26: Losses Deepen Despite Revenue Surge",
        "link": "https://www.marketsmojo.com/news/result-analysis/oxygenta-pharmaceutical-q3-fy26-losses-deepen-despite-revenue-surge-3822462",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/OxygentaPharmac_quaterlyResult_3822462.png",
        "date": "2026-02-05 09:52:51",
        "description": "Oxygenta Pharmaceutical Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹226.00 crores, reported a net loss of ₹4.84 crores for Q3 FY26 (October-December 2025), representing a marginal improvement of 1.83% quarter-on-quarter but a 23.16% deterioration year-on-year. The stock, trading at ₹60.00 as of February 5, 2026, declined 1.70% on the day, reflecting investor concerns about the company's persistent inability to achieve profitability despite robust top-line growth."
      },
      {
        "title": "Why is Oxygenta Pharmaceutical Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-oxygenta-pharmaceutical-ltd-fallingrising-3812242",
        "imagepath": "",
        "date": "2026-01-31 00:53:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Despite opening the day with a gap down of 2%, the stock demonstrated resilience by rallying to an intraday high of ₹64, marking a 6.84% increase from its low point of ₹58.7. This intraday recovery highlights strong buying interest during the session, even as the weighted average price suggests that a larger volume of shares traded closer to the day’s lower price levels. The stock’s ability to rebound from its opening weakness indicates underlying demand that has helped sustain its upward trajectory.</p>\n<p>Oxygenta Pharmaceutical has been on a positive streak, recording gains over the last two consecutive days with an aggregate return of 8.64%. This recent rally is part of a broader trend, as the stock has delivered a remarkable 16.67..."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3804670",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/OxygentaPharmac_mojoScore_3804670.png",
        "date": "2026-01-26 10:10:05",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Stock Falls to 52-Week Low of Rs.51.31",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-stock-falls-to-52-week-low-of-rs5131-3798802",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/OxygentaPharmac_priceRelatedfactors_3798802.png",
        "date": "2026-01-21 12:07:03",
        "description": "Oxygenta Pharmaceutical Ltd’s shares declined to a fresh 52-week low of Rs.51.31 on 21 Jan 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3792870",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/OxygentaPharmac_mojoScore_3792870.png",
        "date": "2026-01-15 10:10:03",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3780585",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/OxygentaPharmac_mojoScore_3780585.png",
        "date": "2026-01-04 10:10:04",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3768644",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/OxygentaPharmac_mojoScore_3768644.png",
        "date": "2025-12-24 20:23:06",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 December 2025, providing investors with the latest insights into its performance and outlook."
      }
    ],
    "total": 215,
    "sid": "798135",
    "stock_news_url": "https://www.marketsmojo.com/news/oxygenta-pharmaceutical-798135"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 04.02.2026.",
      "datetime": "04-Feb-2026",
      "details": "With reference to the subject cited this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited at its Meeting held on Wednesday 04th February 2026 at 12:00 noon at the corporate office of the Company considered and approved the following: 1. Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 2. Limited Review Report for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 3. Re-constitution of Internal Complaints Committee (ICC) constituted under The Sexual Harassment of Women at Workplace (Prevention Prohibition and Redressal) Act 2013 (POSH Act) w.e.f. 04.02.2026. (Attached as Annexure -I)",
      "source": "BSE"
    },
    {
      "caption": "Un-Audited Results For The Quarter And Nine Months Ended 31.12.2025.",
      "datetime": "04-Feb-2026",
      "details": "Un-audited Results for the Quarter and nine months ended 31.12.2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter Ended December 31 2025. 2. Limited Review Report For The Quarter Ended December 31 2025. 3. Any Other Business With The Permission Of The Chair.",
      "datetime": "30-Jan-2026",
      "details": "Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 inter alia to consider and approve 1. Un-audited Financial results for the quarter ended December 31 2025. 2. Limited Review Report for the quarter ended December 31 2025. 3. Any other business with the permission of the Chair.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-02-06 10:10:03

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with the most recent insights into the company’s performance and outlook.

Read full news article

Are Oxygenta Pharmaceutical Ltd latest results good or bad?

2026-02-05 19:29:52

Oxygenta Pharmaceutical Ltd's latest financial results for the quarter ending December 2025 present a complex picture of growth and ongoing operational challenges. The company reported a significant revenue surge of 137.27% quarter-on-quarter, reaching ₹33.93 crores, which reflects a seasonal demand typical in the pharmaceutical sector. However, this top-line growth did not translate into profitability, as the company experienced a net loss of ₹4.84 crores, representing a 23.16% decline year-on-year. The operational metrics indicate persistent difficulties. The operating loss widened to ₹4.08 crores, with an operating margin of negative 12.02%. While this margin shows some improvement from the previous quarter, it remains a concern, especially given the negative operating margins reported in the same quarter last year. The company's negative book value of ₹-6.77 per share raises fundamental questions about...

Read full news article

Oxygenta Pharmaceutical Q3 FY26: Losses Deepen Despite Revenue Surge

2026-02-05 09:52:51

Oxygenta Pharmaceutical Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹226.00 crores, reported a net loss of ₹4.84 crores for Q3 FY26 (October-December 2025), representing a marginal improvement of 1.83% quarter-on-quarter but a 23.16% deterioration year-on-year. The stock, trading at ₹60.00 as of February 5, 2026, declined 1.70% on the day, reflecting investor concerns about the company's persistent inability to achieve profitability despite robust top-line growth.

Read full news article

Why is Oxygenta Pharmaceutical Ltd falling/rising?

2026-01-31 00:53:34

Recent Price Movement and Market Context

Despite opening the day with a gap down of 2%, the stock demonstrated resilience by rallying to an intraday high of ₹64, marking a 6.84% increase from its low point of ₹58.7. This intraday recovery highlights strong buying interest during the session, even as the weighted average price suggests that a larger volume of shares traded closer to the day’s lower price levels. The stock’s ability to rebound from its opening weakness indicates underlying demand that has helped sustain its upward trajectory.

Oxygenta Pharmaceutical has been on a positive streak, recording gains over the last two consecutive days with an aggregate return of 8.64%. This recent rally is part of a broader trend, as the stock has delivered a remarkable 16.67...

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-01-26 10:10:05

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Oxygenta Pharmaceutical Ltd Stock Falls to 52-Week Low of Rs.51.31

2026-01-21 12:07:03

Oxygenta Pharmaceutical Ltd’s shares declined to a fresh 52-week low of Rs.51.31 on 21 Jan 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-01-15 10:10:03

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-01-04 10:10:04

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2025-12-24 20:23:06

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 December 2025, providing investors with the latest insights into its performance and outlook.

Read full news article

View All News